Publications

Posters and Presentations

12/01/2023

Determinants of Health-Related Quality of Life of Patients With Focal Epilepsy: A Systematic Literature Review

12/01/2023

Characterization of BHV-7000: A Novel Kv7.2/7.3 Activator for the Treatment of Seizures

12/01/2023

Novel, Selective Kv7.2/7.3 Potassium Channel Activator, BHV-7000, Demonstrates Dose-Dependent Pharmacodynamic Effects on EEG Parameters in Healthy Adults

12/01/2023

Functional Impairments in Patients With KCNQ2-DEE: Associations Among Key Clinical Features

12/01/2023

A First in Human Phase 1 Study Evaluating the Safety and Tolerability of BHV-7000, a Novel, Selective Kv7.2/7.3 Potassium Channel Activator, in Healthy Adults

09/02/2023

Discovery and Characterization of BHV-7000: A Novel Kv7.2/7.3 Activator for the Treatment of Epilepsy

03/13/2023

Discovery and Characterization of BHV-7000: A Novel Kv7.2/7.3 Activator for the Treatment of Epilepsy

12/03/2022

Effects of retigabine and the novel M-current activator BHV-7000 on epilepsy-associated KCNQ2 variants

09/13/2023

Characterization of the Functional Efficacy of KB-1754, a Novel Kv7 Activator, on Smooth Muscle Contractility

5/25/2023

Understanding the Spectrum of SCA1, SCA2, SCA3, and SCA6 Through the Eyes of Patients: Burden of Illness Perspectives.

6/1/2023

Two Randomized, Double-Blind, Placebo-Controlled Trials of Adjunctive Troriluzole, a Novel Glutamate-Modulating Agent, in Obsessive-Compulsive Disorder

11/17/2022

Two Randomized, Double-Blind, Placebo-Controlled Trials of Adjunctive Troriluzole, a Novel Glutamate-Modulating Agent, in Obsessive-Compulsive Disorder

09/07/2023

BHV-2100, a First-in-Class TRPM3 Antagonist for the Treatment of Neuropathic Pain

10/14/2023

10/14/2023

Taldefgrobep Alfa Reduces Fat and Increases Muscle in an Obese Mouse Model

Correlation Between Reduction in Total Body Weight and Change in Waist Circumference

07/01/2023

Taldefgrobep Alfa: The Phase 3 RESILIENT Study in Spinal Muscular Atrophy

06/20/2023

Taldefgrobep Alfa: Preclinical and Clinical Data Supporting the Phase 3 RESILIENT Study in Spinal Muscular Atrophy

03/20/2023

Taldefgrobep Alfa: Preclinical and Clinical Data Supporting the Phase 3 RESILIENT Study in Spinal Muscular Atrophy